logo-loader

Alternus Energy completes acquisition of three solar parks in Italy from Liquid Sun Srl

Published: 08:20 15 Jan 2019 EST

Solar panels
The solar assets represent a total of 2.24 megawatts of installed power in the Budrio and Anagni regions of Italy

Alternus Energy Inc (OTCMKTS:ALTN)  said Tuesday that it has completed the acquisition of three Italian solar photovoltaic parks from Liquid Sun Srl.

The New York-based renewable energy company said in a press release that under the deal announced in late 2017, its subsidiary PC Italia 02 Srl paid €3.65 million ($4.25 million) for assets, agreements and liabilities related to the ownership and operation of the three power plants. They represent a total of 2.24 megawatts of installed power in the Budrio and Anagni regions of Italy.

READ: Alternus Energy powers up its portfolio, scouting out solar parks across Europe

The solar parks, according to Alternus, have been operating for almost five years and add about €600,000 ($700,000) in annual revenue to the company, with operating margins of more than 85%.

The parks benefit from feed-in-tariff government incentives that guarantee a fixed sales price for every megawatt of energy that the parks generate over 20 years from the date of construction, Alternus said.

The company has a backlog of about €9.5 million ($11 million) of contracted revenue over the next 15 years.

“It is personally very pleasing to finally complete this acquisition that we announced in late 2017,”  Vincent Browne, CEO, president and chairman of Alternus, said in a statement. “It emphasizes our continued commitment and growth in the Italian market going forward with additional strategic acquisitions in the pipeline there.”

To fund the acquisition and related costs, Alternus said it issued a loan note in the aggregate principal amount of €3.8 million with annual interest at 12% per annum and having a six-month term.

The company added that it is in negotiation with an Italian bank to provide project financing for the solar parks. If completed, the financing will replace the note with more suitable long-term financing, according to Alternus.

Shares slipped US$0.03 to US$0.11 in Monday’s OTC Markets trading.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

15 hours, 29 minutes ago